Happy New Year to all! I hope that you were able to enjoy quality time over the holidays with family and friends. It is time to begin discussing our plans for the new year again, but I would first like to review a few highlights from 2021 that laid the foundation for Golden Helix’s future. Golden Helix had a resoundingly successful year with many positive takeaways; below are just a few key highlights from an overwhelmingly momentous year.
We were named on the Inc. 5000 list of Fastest-Growing Private Companies for the 3rd consecutive year. This is a testament to the dedication, ingenuity, and work ethic of the entire Golden Helix team. This accomplishment was achieved only through the loyalty and commitment of the customers, partners, and Golden Helix team.
Golden Helix was also featured by Medhealth Outlook, Mirror Review, and Business APAC as a leading vendor in the Biotech Solutions and Precision Medicine industry. We appreciate the recognition we are receiving globally and look forward to continuing leading the charge into 2022.
We also launched three successful releases of our solutions. VarSeq saw updates to improve whole-exome workflows, improving CNV calling, support for Gene Panels and customized reporting, and more. Also, we published another SVS release which continues to be a highly demanded research tool for GWAS, genomic prediction, and research-oriented DNA-Seq workflows.
Based on all this, we have developed ambitious goals for 2022!
Continuous Software Enhancement
Firstly, we will continue to enhance clinical workflows for cancer and hereditary diseases based on the feedback of our global customer base which we are meticulously capturing and continuously assessing. This allows us to monitor and amplify our solutions as the field of precision medicine continues to evolve.
Secondly, our customers are handling steadily increasing data volumes. In order to continue providing top-level software for our high-end customers facing these increases, we are focusing on the scalability, efficiency, and performance of our software.
Quality & Regulatory Compliance
Thirdly, we recognize that we are operating in a key part of the precision medicine field that is facing regulatory scrutiny now and in the future. Golden Helix is preparing itself for future requirements and the necessary responses for the expected increased regulations in the NGS analytics space.
Employee Development and Growth
Finally, it is exceptionally important to us that Golden Helix is a stimulating and rewarding work environment for our team. In 2022 we will continue to cultivate an atmosphere that fosters growth and encourages ingenuity and dedication so that we may continue to provide the best products and services for our customers.
We appreciate the incredible support and loyalty of our customers and partners. It is only possible through you that Golden Helix can continue providing industry-leading solutions. On behalf of the Golden Helix team, we would like to thank you from the bottom of our hearts, and we are looking forward to another tremendous year together.